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Introduction: Src tyrosine kinase overactivation has been correlated with a poor response to human epidermal
growth factor receptor 2 (HER2) inhibitors in breast cancer. To identify the mechanism by which Src overexpression
sustains this resistance, we tested a panel of breast cancer cell lines either sensitive or resistant to lapatinib.
Methods: To determine the role of Src in lapatinib resistance, we evaluated the effects of Src inhibition/silencing
in vitro on survival, migration, and invasion of lapatinib-resistant cells. In vivo experiments were performed in JIMT-1
lapatinib-resistant cells orthotopically implanted in nude mice. We used artificial metastasis assays to evaluate the
effect of Src inhibition on the invasiveness of lapatinib-resistant cells. Src-dependent signal transduction was
investigated with Western blot and ELISA analyses.
Results: Src activation was higher in lapatinib-resistant than in lapatinib-sensitive cells. The selective small-molecule Src
inhibitor saracatinib combined with lapatinib synergistically inhibited the proliferation, migration, and invasion of
lapatinib-resistant cells. Saracatinib combined with lapatinib significantly prolonged survival of JIMT-1-xenografted mice
compared with saracatinib alone, and impaired the formation of lung metastases. Unexpectedly, in lapatinib-resistant
cells, Src preferentially interacted with epidermal growth factor receptor (EGFR) rather than with HER2. Moreover, EGFR
targeting and lapatinib synergistically inhibited survival, migration, and invasion of resistant cells, thereby counteracting
Src-mediated resistance. These findings demonstrate that Src activation in lapatinib-resistant cells depends on EGFR-
dependent rather than on HER2-dependent signaling.
Conclusions: Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to
lapatinib in breast cancer.Introduction
Human epidermal growth factor receptor 2 (HER2) is a
transmembrane receptor tyrosine kinase (RTK) and a
member of the HER family that includes HER1, known as
epidermal growth factor receptor (EGFR), human epider-
mal growth factor receptor 3 (HER3), and human epider-
mal growth factor receptor 4 (HER4). It controls growth,
differentiation, and cell survival through dimerization with
other HER receptors, most notably HER3 and EGFR.* Correspondence: robianco@unina.it
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distribution, and reproduction in any mediumHER2-dependent signaling is mediated by various down-
stream pathways, all of which include activation of mul-
tiple intracellular effectors, such as mitogen-activated
protein kinase (MAPK) and phosphoinositide 3-kinase
(PI3K)/Akt [1]. HER2 amplification occurs in approxi-
mately 25% of breast cancers and correlates with a poor
prognosis and resistance to conventional antitumor ther-
apies [2,3]. However, it is also an important target for anti-
HER2 drugs, namely, monoclonal antibodies that target
the extracellular domain of the receptor, such as trastuzu-
mab and pertuzumab, small-molecule adenosine triphos-
phate (ATP) competitors able to block tyrosine kinase
(TK) activity within the intracellular domain of HER2,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trastuzumab emtansine [4,5]. Lapatinib, a dual inhibitor
able to target also the TK domain of HER1 [6,7], has been
approved for the treatment of patients with HER2-positive
metastatic breast cancer after trastuzumab failure. When
given in combination with capecitabine, this agent signifi-
cantly improves time to progression [8]. Combined with
paclitaxel, lapatinib is active as first-line treatment [9]. Un-
fortunately, some patients are constitutively resistant to
lapatinib treatment, and, even in responders, the disease
often progresses because of the selection of tumor cells
that have acquired resistance to the drug.
Resistance to lapatinib occurs via various mechanisms:
HER2 alterations, aberrant activation of escape pathways
mediated by other RTKs or intracellular signaling effec-
tors, co-expression of the truncated p95 HER2 receptor
[9], and changes in apoptosis or cell-cycle regulation.
Based on these findings, various therapeutic approaches
are being investigated in the attempt to overcome resist-
ance to lapatinib in breast cancer patients [10].
Src family kinases are nonreceptor TKs that interact
with several transmembrane receptors, including mem-
bers of the HER family, insulin-like growth factor-1 re-
ceptor, and c-Met. Through these interactions, Src
controls cell growth and survival by modulating the ac-
tivity of such intracellular effectors as PI3K/Akt and sig-
nal transducer and activator of transcription 3 (STAT3)
[11]. Src also is involved in the phosphorylation of focal
adhesion kinase (FAK), paxillin, RhoA, and other mole-
cules, and therefore it is implicated in the regulation of
cancer cell migration and invasion [12]. Src activation
has been described as a determinant of resistance to anti-
EGFR drugs in human lung, colorectal, and pancreatic
cancer cell models [13-15]. For example, Src contributes
to c-Met activation in gefitinib-resistant non-small cell
lung cancer cells [16]. Moreover, Src activation has been
associated with resistance to the anti-HER2 drugs trastu-
zumab [17] and lapatinib [18] in HER2-overexpressing
breast cancer cells. Despite the large body of data on the
interactions between Src and HER2 in breast cancer
[19-21], it is still unclear how Src activation is able to trig-
ger and sustain resistance to anti-HER2 antagonists.
In this study, we investigated the role of Src in intrin-
sic and acquired lapatinib resistance in human breast
cancer cell lines overexpressing HER-2, both in vitro and
in vivo. We also evaluated the effects of the Src inhibitor
saracatinib (AZD0530), alone and combined with lapati-
nib, as a therapeutic strategy in breast cancer models re-
sistant to lapatinib.
Materials and methods
Compounds and cell cultures
Lapatinib and saracatinib were purchased from Selleck
Chemicals, Munich, Germany. Cetuximab was provided byImClone Systems NJ, USA. Human breast cancer cell lines
MDA-MB-361, SKBR-3, and BT474 were obtained from
the American Type Culture Collection. The KPL4 cell line
was isolated from the malignant pleural effusion of a breast
cancer patient with an inflammatory skin metastasis; these
cells are resistant to trastuzumab in female athymic nude
mice [22]. The JIMT-1 cell line was established from a
pleural metastasis of a 62-year-old breast cancer patient
who was clinically resistant to trastuzumab.
Ethical approval by the local ethical committees and
patient consent were obtained for the use of KPL4 and
JIMT-1 cells. Ethical approval was obtained from the
University of Tampere and Tampere University Hospital,
Finland, for the JIMT-1 cells. Use of the KPL4 cells was
approved by the Kawasaki Medical School, Kurashiki,
Okayama, Japan. JIMT-1 cells form trastuzumab-resistant
xenograft tumors in nude mice [23]. MDA-MB-361
lapatinib-resistant (LR) cells were generated by using a vali-
dated protocol of in vivo/in vitro selection after prolonged
exposure to the drug [24]. All cell lines were authenticated
by using DNA fingerprinting and maintained in RPMI
medium supplemented with 10% heat-inactivated fetal bo-
vine serum, 20 mM HEPES, pH 7.4, penicillin (100 IU/ml),
streptomycin (100 μg/ml), and 4 mM glutamine (ICN,
Irvine, UK) in a humidified atmosphere of 95% air and 5%
CO2 at 37°C.
MTT survival assay
Cells (104 cells/well) were grown in 24-well plates and ex-
posed for 72 hours to increasing doses of lapatinib, saracati-
nib, cetuximab, or their combinations. The percentage of
cell survival was determined by using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT).
The half-maximal inhibitory concentration (IC50) for
each drug was calculated by GraphPad Prism 5.0 soft-
ware, normalizing the response between 0 and 100%.
Wound-healing assay
Cancer cell-line monolayers grown to confluence on
gridded plastic dishes were wounded by scratching them
with a 200-μl pipette tip, and then grown in the presence
or absence of each drug (saracatinib, lapatinib, or cetuxi-
mab) alone or in combinations. The wounds were photo-
graphed (10× objective) at 0 and 24 hours, and healing
was quantified by measuring the distance between the
edges of the wound by using Adobe Photoshop (v. 8.0.1;
Adobe Systems, Inc., San Jose, CA, USA). The results are
reported as the percentage of the total distance of the ori-
ginal wound enclosed by cells.
Invasion assay
The invasive potential of cancer cells was determined by
using a model based on co-culture with fibroblasts, as
previously described [25]. In brief, fibroblasts were
Formisano et al. Breast Cancer Research 2014, 16:R45 Page 3 of 15
http://breast-cancer-research.com/content/16/3/R45seeded (104 cells/well) in 24-well plates. After conflu-
ence, cells were permeabilized with dimethyl sulfoxide
(DMSO; 500 μl) and subsequently overlaid with tumor
cells. One hour later, the individual wells were treated
with saracatinib, lapatinib, or cetuximab, or their combi-
nations. Eighteen hours later, cells were incubated for
15 minutes with 0.2% trypan blue/phosphate-buffered
saline (Mediatech, Herndon, VA, USA). To measure in-
vasion, cells were lysed with 100 μl of 1% sodium dodecyl
sulfate/phosphate-buffered saline. Absorbance was mea-
sured with a microplate Synergy HT-Bioteck at 610 nm
and compared with the absorbance of fibroblasts not over-
laid with tumor cells. The results were expressed as per-
centage of invasion of the fibroblast monolayer with the
following formula: X = 100% (cell line and fibroblast well
absorbance/fibroblast well absorbance) [25].
Immunoprecipitation and Western blot analyses
Total cell lysates from cell cultures or tumor specimens
were resolved by 4% to 15% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and probed
with anti-human antibodies (see Additional file 1). Co-
immunoprecipitation analyses were performed with anti-
Src, anti-HER2, or anti-EGFR antibodies; membranes
were blotted with anti-Src, anti-HER2, anti-EGFR, or anti-
HER3 antibodies. The total lysate from BT474 cells served
as positive control. Immunoreactive proteins were visual-
ized by enhanced chemiluminescence (Pierce, Rockford,
IL, USA). Densitometry was performed with Image J soft-
ware (NIH, Bethesda, MD, USA). Details of the complete
procedure are reported in Additional file 1.
RNA interference
Small interfering RNA (siRNA) against EGFR and Src
were obtained from Invitrogen Life Technologies and
Ambion Life Technology (Grand Island, NY, USA), re-
spectively. A nonsense sequence was used as negative
control. Details of the complete procedure are reported
in Additional file 1.
Transfection of human EGFR and EGFR-Tyr845Phe
Human wild-type EGFR or mutant EGFR-Tyr845Phe
(Y845F) was cloned into a pcDNA vector. MDA-MB-361
cells were transiently transfected by using the Lipofectamine
2000 reagent (Invitrogen), according to the manufacturer’s
instructions. Twenty-four hours after transfection, the cells
were treated with lapatinib (0.2 μM) for 3 consecutive days
and analyzed with MTTassay.
Nude mice cancer xenograft models
Five-week-old Balb/c athymic (nu+/nu+) mice (Charles
River Laboratories, Milan, Italy), maintained in accordance
with the guidelines of the University of Naples “Federico II”
Animal Care Committee (ethical approval protocolnumber 65), were injected orthotopically in the fourth
mammary fat pad, with JIMT-1 cells (107 cells/mouse)
resuspended in 200 μl of Matrigel (CBP, Bedford, MA,
USA). Seven days later, when tumors became detect-
able, mice (10/group) were randomized to receive lapa-
tinib, 100 mg/kg intraperitoneally (i.p.) 5 times per
week for 3 weeks; saracatinib, 50 mg/kg via oral gavage
5 times per week for 3 weeks; cetuximab, 10 mg/kg i.p.
twice a week for 3 weeks, or their combinations. Animals
treated with dimethyl sulfoxide (DMSO) vehicle served as
controls. Tumor volume (cm3) was measured by using the
formula π/6 × largest diameter × (smallest diameter)2 [26].
Experimental metastasis assay
Before inoculation with JIMT-1 cells, mice (six mice/
group) were treated with lapatinib (100 mg/kg, i.p.), sar-
acatinib (50 mg/kg per os) or both for a week. Then
30 × 105 cells were injected into each animal’s tail vein,
after which mice were treated with lapatinib, saracatinib,
or both for 7 consecutive days. All mice were killed 21 days
after the injection of tumor cells [27]. Human DNA in all
lobes of the lungs of the mice was measured by quantify-
ing Alu sequences by polymerase chain reaction, as de-
scribed elsewhere [28] and detailed in Additional file 1.
Statistical analysis
The results of in vitro experiments were analyzed with
Student t test and expressed as means and standard devia-
tions (SDs) for at least three independent experiments per-
formed in triplicate. The statistical significance of tumor
growth was determined by one-way ANOVA and the
Dunnett multiple comparison posttest, whereas the log-
rank test was used to determine the statistical significance
of mouse survival. All reported P values were two-sided.
Analyses were performed with the BMDP New System
statistical package version 1.0 for Microsoft Windows
(BMDP Statistical Software, Los Angeles, CA, USA).
Results
Saracatinib combined with lapatinib synergistically inhibits
survival of lapatinib-resistant human breast cancer cell lines
We first evaluated the effect of lapatinib in a panel of
HER2-positive cells: MDA-MB-361, SKBR-3, BT474,
KPL4, and JIMT-1. As shown in Figure 1A and in
Additional file 2: Figure 1A, lapatinib was very active
against SKBR-3 (IC50 = 0.11 μM), BT474 (IC50 = 0.06 μM)
and MDA-MB361 (IC50 = 0.18 μM); KPL-4 cells were
moderately sensitive (IC50 = 0.47 μM) and JIMT-1 cells
were resistant (IC50 = 1.9 μM). MDA-MB-361 cells have
been reported to be lapatinib resistant in two studies
[29,30] and lapatinib sensitive in another study [18]. In
our hands, MDA-MB-361 cells were efficiently inhibited
by lapatinib both in vitro and in vivo (data not shown).
We also generated an MDA-MB-361 lapatinib-resistant
Figure 1 (See legend on next page.)
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Figure 1 Saracatinib combined with lapatinib synergistically inhibits survival of human breast cancer cell lines. (A) Percentage of survival
of MDA-MB-361, SKBR-3, BT474, KPL-4, MDA-MB-361-LR, and JIMT-1 breast cancer cell lines grown in complete medium and treated with saracatinib,
lapatinib, or both, measured by MTT assay. Data represent the mean (±standard deviation, SD) of three independent experiments, each performed in
triplicate, and are presented relative to control (cells treated with DMSO). Error bars indicate SDs. Asterisks indicate statistical significance of combined
treatment versus lapatinib alone determined with Student t test (*two-sided P < 0.5 × 10−1; **two-sided P < 0.5 × 10−2). (B) Western blot analysis of total
cell lysates from MDA-MB-361, SKBR-3, BT474, KPL-4, MDA-MB-361-LR, and JIMT-1 breast cancer cell lines grown in complete medium. (C) Western blot
analysis of total cell lysates from breast cancer cell lines grown in complete medium and treated with saracatinib (1 μM), lapatinib (1 μM), or both. The
relative optical density of phospho-protein levels normalized to actin level is shown.
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cells by using a validated protocol of in vivo/in vitro selec-
tion [24] after prolonged exposure to the drug. In these de-
rivative lapatinib-resistant cells, the IC50 was reached at the
dose of 1.1 μM (Figure 1A and Additional file 2: Figure 1A).
We also tested the effects of the Src inhibitor saracatinib
on all the previously described cell lines. Saracatinib alone
marginally affected survival of all tested breast cancer cells
(IC50 ranging between 0.8 and 2.0 μM), whereas the sara-
catinib/lapatinib combination exerted a statistically signifi-
cant inhibitory effect in lapatinib-resistant cells (Figure 1A
and Additional file 3: Table S1). In the attempt to shed
light on the interaction and the possible synergism be-
tween saracatinib and lapatinib, we measured the combin-
ation index (CI) devised by Chou and Talalay by using
an automated calculation software (CalcuSyn Soft.)
[31]. A combination is deemed synergistic when the CI
is <1.0, and highly synergistic when the CI is <0.5. As
shown in Additional file 2: Figure S1B, the saracatinib/
lapatinib combination was highly synergistic in KPL4
cells (median CI, 0.046 ± 0.022), and in lapatinib-resistant
cell lines (median CI, 0.21 ± 0.089 for MDA-MB-361-LR,
0.37 ± 0.084 for JIMT-1). The saracatinib/lapatinib com-
bination was not synergistic in MDA-MB-361, SKBR-3, or
BT474 cells (data not shown). Details of the combination
effect calculation are reported in Additional file 1.
Our study of the activation of HER2-dependent signal-
ing in breast cancer cells demonstrated increased levels
of Src phosphorylation at tyrosine 416 (Y416) in the
lapatinib-resistant cells (MDA-MB-361-LR and JIMT-1),
whereas levels of phosphorylated HER2 were unchanged
(Figure 1B). Therefore, we examined the effects of saraca-
tinib, lapatinib, and their combination on HER-dependent
signal transduction. Saracatinib slightly inhibited HER2-
related transducers in MDA-MB-361, SKBR-3, MDA-MB-
361-LR, and JIMT-1 cells. It efficiently reduced Src
activity in all these cells (Figure 1C). Lapatinib reduced
HER2, Akt, and MAPK phosphorylation/activation in
the lapatinib-sensitive MDA-MB-361 and SKBR-3 cells.
It also reduced HER2 phosphorylation in MDA-MB-
361-LR and JIMT-1 cells (about 50% in both cell lines),
but its effect on Akt and MAPK phosphorylation was
significantly lower in resistant cells than in sensitive MDA-
MB-361 and SKBR-3 cells. In all cell lines, inhibition ofsignal transduction was greater in cells treated with the sar-
acatinib/lapatinib combination than in cells treated with a
single agent. It almost completely suppressed pHER2,
pAkt, pSrc, and pMAPK levels (Figure 1C).
A combination of saracatinib and lapatinib efficiently
blocks the migration and invasion of lapatinib-resistant
human breast cancer cell lines
Because Src activation is a well-known driver of tumor
metastasis, we investigated the effects of its inhibition
on the migration and invasive potential of breast cancer
cells sensitive or resistant to lapatinib. In the absence of
drugs, resistant cells were more aggressive than sensitive
cells, as witnessed by their higher migration (Figure 2A)
and invasion (Figure 2B). Treatment with low doses of
saracatinib inhibited migration of all human breast can-
cer cell lines in a wound-healing assay, whereas lapatinib
did not exert any effect (Figure 2C). The combination of
saracatinib and lapatinib strongly inhibited migration in
the lapatinib-resistant MDA-MB-361-LR and JIMT-1 cells,
whereas this effect was less pronounced in the lapatinib-
sensitive MDA-MB-361 and SKBR-3 cells (Figure 2C and
Additional file 4: Table S2). In addition, whereas neither
saracatinib nor lapatinib alone significantly affected inva-
sion of a fibroblast monolayer by breast cancer cells, the
combined treatment did, even in lapatinib-resistant cells.
The results were less evident in SKBR-3 cells, because of
their low-motility capabilities (Figure 2D and Additional
file 4: Table S2); for the same reason, BT474 and KPL4
cells were not included in the analysis.
We next analyzed the effect of the saracatinib/lapatinib
combination on signal transducers involved in cell migra-
tion and invasion (Figure 2E). Whereas saracatinib treat-
ment decreased pFak, ppaxillin, and pp130Cas levels in
MDA-MB-361-LR and JIMT-1 cell lines, lapatinib alone
was less effective. Notably, saracatinib plus lapatinib treat-
ment resulted in reduction of all the previously cited me-
diators, which is in line with their inhibitory effects on
migration and invasion processes (Figure 2E).
Saracatinib combined with lapatinib induces a
cooperative antitumor effect on JIMT-1 tumor xenografts
To test the efficacy of the saracatinib/lapatinib combin-
ation and of each agent given alone in vivo, we
Figure 2 Saracatinib combined with lapatinib efficiently blocks migration and invasion of human breast cancer cell lines. (A) Percentage of
migration of MDA-MB-361, MDA-MB-361-LR, JIMT-1, KPL-4, SKBR-3, and BT474, human breast cancer cell lines grown in complete medium measured
by wound-healing assay. Results are presented as the percentage of the total distance of the original wound enclosed by cells. (B) Percentage
of invasion of MDA-MB-361, MDA-MB-361-LR, JIMT-1, KPL-4, SKBR-3, and BT474 human breast cancer cell lines grown in complete medium,
measured by fibroblast monolayer invasion assay. Results are expressed as percentage of monolayer fibroblast invasion. (C) Percentage of migration of
MDA-MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 treated with saracatinib (0.2 μM), lapatinib (1 μM), or both, measured by wound-healing assay. The
results are presented as the percentage of the total distance of the original wound enclosed by cells. (D) Percentage of invasion of MDA-MB-361,
SKBR-3, MDA-MB-361-LR, and JIMT-1 treated with saracatinib (0.2 μM), lapatinib (1 μM), or both measured by fibroblast monolayer invasion
assay. Results are expressed as percentage of invasion of fibroblast monolayer. (E) Western blot analysis of total cell lysates from MDA-MB-361,
SKBR-3, MDA-MB-361-LR, and JIMT-1 treated with saracatinib (0.2 μM), lapatinib (1 μM), or both. The data represent the mean (±standard
deviation, SD) of three independent experiments, each performed in triplicate, and are presented relative to control (cells treated with DMSO).
Error bars indicate SDs. Asterisks indicate statistical significance of combined treatment versus lapatinib alone, determined with Student t test
(*two-sided P < 0.5 × 10−1; **two-sided P < 0.5 × 10−2). The relative optical density of phosphoprotein levels normalized to the actin level is shown.
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cells in Balb/C nude mice, and measured both tumor
growth and survival. As shown in Figure 3A, in un-
treated mice, the tumor reached the maximum allowed
size (about 2 cc, on day 63, which was 9 weeks after the
injection of tumor cells. At this time, saracatinib and
lapatinib inhibited tumor growth by 37% and 13%, re-
spectively, whereas the saracatinib/lapatinib combination
inhibited tumor growth by 75%. In lapatinib-treated
mice, tumors reached 2 cc on day 77, 10 weeks after
tumor injection versus day 98 (14 weeks after tumor in-
jection) in saracatinib-treated mice. Saracatinib plus
lapatinib synergistically exerted a potent long-lastingantitumor effect: 42% growth inhibition (tumor size,
1.16 cm3) at the end of the experiment (day 105). At
ANOVA test, tumors were significantly larger in mice
treated with a single agent than in combination-treated
mice (combination versus single agents, P < 0.1 × 10−2 at
the median survival of the control group) (Figure 3A).
Consistently, median survival was significantly longer in
mice treated with the saracatinib/lapatinib combination
than in both control mice (median survival, 102.50 ver-
sus 32.50 days; hazard ratio, 0.03751; 95% confidence
interval, 0.009463 to 0.1487; P < 0.1 × 10−3) and in mice
treated with saracatinib alone (median survival, 102.50
versus 61.50 days; hazard ratio, 0.1785; 95% confidence
Figure 3 Saracatinib combined with lapatinib induces a cooperative antitumor effect in JIMT-1 tumor xenografts. (A) Seven days after
orthotopic injection of JIMT-1 cells, mice were randomized (10/group) to receive lapatinib, saracatinib, or both (see Materials and methods section
for details). The control group is constituted of animals treated with DMSO vehicle. The one-way ANOVA test was used to compare tumor sizes
among treatment groups at the median survival of the control group (32.5 days). Tumors were significantly smaller in animals administered the
combination than in mice treated with a single agent (P < 0.1 × 10−2). (B) Median survival was significantly longer in animals injected with the
combination versus control animals (P < 0.1 × 10−2) and saracatinib-treated animals (P < 0.5 × 10−2), evaluated by log-rank test. (C) Experimental
metastasis assay. Percentage of human Alu sequences in the lungs of mice after tail-vein injection with JIMT-1 cells and treatment with lapatinib,
saracatinib, or both (see Materials and methods section for details). Data are calculated by using mean cycle-threshold values. (D) Western blot
analysis of total lysates from JIMT-1 tumor specimens of two mice killed on day 25. Tumors derived from each treatment group were pooled
during lysis to obtain a single specimen. The relative optical density of phosphoprotein levels normalized to the actin level is shown.
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Treatments were well tolerated; no weight loss or other
signs of acute or delayed toxicity were observed. No
spontaneous macrometastases were found in brains,
lungs, spleens, or livers after death in any of the mouse
groups.
To investigate the effect of saracatinib and lapatinib on
tumor metastatic behavior, we injected JIMT-1 cells into
the tail vein of Balb/c nude mice and then treated the ani-
mals with saracatinib, lapatinib, or both. Examination ofserial histologic sections of mouse lungs did not reveal
macrometastases (data not shown). To identify micro-
metastases in the lung, we measured human DNA in
mice lungs by using real-time polymerase chain reac-
tion (PCR) for human Alu sequences, as previously de-
scribed [28]. Human DNA was detected in the lungs of
untreated mice (Additional file 5: Figure S2). Saracati-
nib was much more effective than lapatinib in reducing
levels of human DNA in mouse lungs. However, as
shown in Figure 3C, combined treatment inhibited the
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versus saracatinib, P < 0.1 × 10−2).
Western-blotting analysis of tumors removed on com-
pletion of treatment revealed that saracatinib reduced
the activated forms of HER2, EGFR, Akt, MAPK, Src,
FAK, paxillin, and p130Cas (Crk-associated substrate). It
also increased the inactive form of Src phosphorylated
on tyrosine 527 (Y527). As expected, lapatinib did not
inhibit HER-dependent signaling in JIMT-1 cells. The
combination of saracatinib and lapatinib inhibited signal
transduction more effectively than did single-agent treat-
ments; it almost completely suppressed the activated
forms of HER2, Akt, MAPK, Src, paxillin, and p130Cas
(Figure 3D).
Src silencing coupled with lapatinib inhibits signal
transduction of lapatinib-resistant human breast cancer
cell lines
Given the antitumor effects induced by saracatinib treat-
ment on lapatinib-resistant cells, in vitro and in vivo, we
used siRNA against Src to exclude off-target effects of sara-
catanib. We found that Src silencing reduced Src levels by
about 40% in MDA-MB-361-LR cells (P = 1.9 × 10−2) and
by 48% in JIMT-1 cells (P = 2 × 10−2) (Figure 4A). Similar
levels of Src reduction were observed in lapatinib-sensitive
MDA-MB-361 and SKBR-3 cells (>80% in both cases). In
resistant cell lines, Src silencing moderately inhibited
EGFR-related transducers, but efficiently reduced Src acti-
vation. Moreover, coupled with lapatinib, it greatly reduced
Src, Akt, and MAPK activation, thereby recapitulating the
effects observed with saracatinib plus lapatinib. Conversely,
in sensitive cells, the combined treatment was not more ef-
fective than lapatinib alone in inhibiting HER2-dependent
signal transduction (Figure 4A).
Src interacts with EGFR rather than with HER2 in
lapatinib-resistant cells
Scr family kinases interact with various transmembrane
receptors, including members of the HER family [20,32],
and regulate several cellular activities. Therefore, we in-
vestigated whether Src participates in HER signaling in
lapatinib-resistant cells by interacting with RTKs. As
shown in Figure 4B, in co-immunoprecipitation experi-
ments, the HER2/Src association was much lower in the
lapatinib-resistant cells MDA-MB-361-LR and JIMT-1
than in the lapatinib-sensitive MDA-MB-361 and SKBR-
3 cells. Conversely, the interaction between EGFR and
Src was much more evident in MDA-MB-361-LR and
JIMT-1 than in sensitive cells. HER3 did not co-
immunoprecipitate with Src. Moreover, the level of HER2/
EGFR heterodimers was greatly reduced, and no HER3/
EGFR heterodimers were found in lapatinib-resistant cells
(Figure 4B). To probe the molecular mechanism under-
lying EGFR activation, we performed ELISA assays for theEGFR ligands EGF and transforming growth factor
(TGF)-α, and found no significant difference in the ex-
pression/secretion of EGFR ligands among the various
lapatinib-sensitive and lapatinib-resistant cell lines (see
Additional file 6: Figure S3A, B). Details of the complete
procedure are reported in Additional file 1.
A site of tyrosine phosphorylation has been identified
within the activation loop of the EGFR TK domain, tyro-
sine 845 (Y845), whose phosphorylation is mediated by
Src [33-35]. Consistent with the enhanced levels of Src ac-
tivation and with the EGFR/Src interaction detected in
lapatinib-resistant cells, EGFR phosphorylation on Y845
was higher in the lapatinib-resistant MDA-MB361-LR and
JIMT-1 cells than in the lapatinib-sensitive cells, whereas
Y1173 phosphorylation did not differ between lapatinib-
resistant and lapatinib-sensitive cells (Figure 4C).EGFR inhibition or silencing partially overcomes lapatinib
resistance in breast cancer cells
To investigate the role of EGFR in Src-mediated lapati-
nib resistance, we evaluated the effect of the anti-EGFR
mAb cetuximab combined with lapatinib on signal
transduction of lapatinib-resistant breast cancer cells.
We found that cetuximab but not lapatinib reduced
EGFR phosphorylation on Tyr1173 (Figure 5A). Interest-
ingly, cetuximab inhibited Src-mediated phosphorylation/
activation of EGFR by reducing levels of phospho-Y845.
Consistently, cetuximab alone reduced Src phosphoryl-
ation in MDA-MB361-LR cells and abolished it in JIMT-1
cells.
A reduction of phospho-Akt and phospho-MAPK
levels was also observed, and this effect was even more
evident with the addition of lapatinib to cetuximab com-
pared with cetuximab alone. Conversely, in lapatinib-
sensitive cells, the lapatinib/cetuximab combination was
not more effective than lapatinib alone in inhibiting sig-
nal transduction (Figure 5A). Moreover, an analysis of
Src-related effectors of cellular motility showed that
combination treatment induced a reduction of the active
forms of FAK, paxillin, and p130Cas (see Additional file
7: Figure S4A).
We next used an EGFR-specific siRNA to verify the
role of EGFR in Src activation in lapatinib-resistant cells,
and found that it reduced EGFR expression levels by
about 43% in MDA-MB-361-LR cells (P = 0.6 × 10−2)
and by 68% in JIMT-1 cells (P = 0.4 × 10−2) (Figure 5B).
This effect was paralleled by a reduction of pSrc levels.
Moreover, as observed after cetuximab treatment, levels
of the phosphorylated forms of Akt and MAPK were re-
duced after treatment with EGFR siRNA, alone or associ-
ated with lapatinib. Conversely, in lapatinib-sensitive cells,
combined treatment was not more effective than lapatinib
alone in inhibiting signal transduction (Figure 5B).
Figure 4 Src contributes to lapatinib resistance in breast cancer cells by interacting with EGFR rather than with HER2. (A) Western blot
analysis of total cell lysates from MDA-MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cell lines transfected with an Src-specific
siRNA (50 nM) and treated or not with lapatinib (1 μM). The siRNA-negative control consists of nontargeting sequences. (B) Immunoprecipitation
using anti-HER2, anti-Src, and anti-EGFR antibodies and blotting with anti-EGFR, −HER2, −HER3, and -Src antibodies of MDA-MB-361, SKBR-3, MDA-
MB-361-LR, and JIMT-1 human breast cancer cells grown in complete medium. Total lysate, not immunoprecipitated, from BT474 cells was used
as positive control. (C) Western blot analysis of total cell lysates from MDA-MB-361, SKBR-3, MDA-MB-361LR, and JIMT-1 human breast cancer cell
lines grown in complete medium. The relative optical density of phospho-protein levels normalized to the actin level is shown.
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Figure 5 EGFR inhibition or silencing partially interferes with signal transduction in lapatinib-resistant breast cancer cells. (A) Western
blot analysis of total cell lysates from MDA-MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cell lines grown in complete
medium and treated with lapatinib (1 μM), cetuximab (0.35 μM), or the combination. (B) Western blot analysis on total cell lysates from MDA-MB-361,
SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cell lines transfected with an EGFR-specific siRNA (5 nM) and treated or not with lapatinib
(1 μM). The relative optical density of phospho-protein levels normalized to the actin level is shown.
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in the onset of lapatinib resistance, we transfected the
sensitive MDA-MB-361 cell line with either the wild-
type EGFR or the mutant Tyr845Phe (Y845F) variant ofEGFR. As shown in Additional file 7: Figure S4B, overex-
pression of wild-type EGFR drastically reduced the in-
hibition of proliferation induced by lapatinib treatment,
an effect partially rescued by the mutant Y845F, which
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and EGFR.
Given that the combination of cetuximab and lapatinib
efficiently blocked signal transduction, we investigated
whether this approach could overcome lapatinib resist-
ance in MDA-MB-361-LR and JIMT-1 cells. In the par-
ental MDA-MB-361 cell line, lapatinib controlled cell
survival; the addition of cetuximab did not increase this
effect (Additional file 8: Figure S5A and Additional file 9:
Table S3). The medium CI, measured with the Chou and
Talalay method [31] and using a constant dose ratio
(2.8:1), was 1.189 ± 2.7 (Additional file 8: Figure S5B).
In the lapatinib-resistant MDA-MB-361-LR and JIMT-1
cells, treatment with lapatinib or cetuximab alone did
not affect cancer cell survival, whereas the combination
of the two drugs at an equipotent ratio greatly reduced
it (Additional file 8: Figure S5A and Table S3). As
shown in Additional file 8: Figure S5B, the synergistic
effect of combination treatment was very strong (median
CI, 0.029 ± 1.83 for MDA-MB-361-LR cells, and 0.204 ±
5.74 for JIMT-1 cells). Conversely, the combination of
cetuximab plus saracatinib was not more effective than
each single agent (see Additional file 10: Figure S6A).
Interestingly, cetuximab partially reduced migration
and invasion of lapatinib-resistant cells. The addition of
cetuximab to lapatinib efficiently blocked the migration
and invasion capabilities of resistant cells (Additional file 8:
Figure S5C, D, and Additional file 11: Table S4), as ob-
served with the saracatinib-plus-lapatinib combination.
Cetuximab combined with lapatinib induces a
cooperative antitumor effect in JIMT-1 tumor xenografts
We tested the effect of cetuximab combined with lapati-
nib also in vivo, in Balb/C nude mice orthotopically
xenografted with the lapatinib-resistant JIMT-1 cells.
When tumors in untreated mice reached the maximum
allowed size, about 2 cc, which occurred on day 49,
cetuximab and lapatinib, given singly, inhibited tumor
growth by 49% and 15%, respectively. The two agents com-
bined reduced tumor growth by 88%. In none of the
treated animals did the tumor size reach 2 cc on day 49,
7 weeks after tumor injection. One-way ANOVA revealed
a significantly longer median survival in mice treated with
the combination than in those treated with single agents
(P < 0.1 × 10−2) evaluated at the median survival period of
the control group (Figure 6A). We were unable to calculate
the median survival of mice treated with the combination
because 90% of the mice were alive on day 49 (Figure 6B).
Treatments were well tolerated; no weight loss or other
signs of acute or delayed toxicity were observed.
As shown in Figure 6C, Western blotting analysis of
tumors removed at the end of treatment revealed that,
as expected, lapatinib did not inhibit HER-dependent
signaling. Cetuximab reduced the activated forms ofEGFR, MAPK, and Src. The effect on the EGFR prob-
ably reflects a reduction of the total EGFR expression
due to cetuximab-induced internalization and degrad-
ation [36]. The cetuximab/lapatinib combination was
even more effective in inhibiting signal transduction
than was each agent administered alone (Figure 6C).
Discussion
This study implicates functional crosstalk between EGFR
and Src in the onset of lapatinib resistance. The combin-
ation of lapatinib with the Src inhibitor saracatinib pre-
vented not only the proliferation and survival of breast
cancer cells, but also cell motility, migration, and inva-
sion. These changes may impair the metastatic spread.
We showed that treatment with saracatinib plus lapati-
nib reduced the formation of lung metastases in nude
mice injected with lapatinib-resistant breast cancer cells.
Consistently, the combined treatment suppressed signaling
pathways that mediate both cell proliferation (PI3K/Akt
and MAPK) and motility (FAK, paxillin, and p130Cas).
More interestingly, Src was overexpressed, and it pref-
erentially bound to and activated EGFR in lapatinib-
resistant models, as demonstrated by the increased levels
of phosphorylation at the Y845 tyrosine residue of the
receptor in both JIMT-1 and MDA-MB-361-LR cells.
EGFR Y845 is a conserved tyrosine within the kinase do-
main in most RTKs, and it plays an important role in
the biologic synergy and cross-talk of EGFR/Src [34]. In
addition, phosphorylation of Y845 on EGFR is required
for cell growth and transformation in breast cancer cell
lines [37]. The importance of EGFR-dependent signaling
in HER2 resistance also emerges from the finding re-
ported by Rexer et al. [38] that BT474 cells, stably trans-
fected with the increased autocatalytic T798M variant of
the HER2 receptor, display increased expression of
EGFR ligands and are efficiently inhibited by the com-
bination of cetuximab and trastuzumab.
It has recently been suggested that acquired resistance
to lapatinib could be sustained by activation of an
HER3/EGFR-dependent pathway that is related to here-
gulin stimulation [39], thereby implicating HER family
receptors other than HER2 in lapatinib resistance. We
can rule out that HER3 was involved in our models of
lapatinib resistance because it did not interact signifi-
cantly with either EGFR or Src.
The alternative activation of RTKs other than HER3 has
been described as a mechanism of resistance to tyrosine
kinase inhibitors [40], and it could, at least in some pre-
clinical models, depend on Src activity. In breast cancer
cells, Met and Src were found to cooperate to overcome
gefitinib-induced EGFR inhibition [41]. In addition, about
20% of human breast cancers overexpress EGFR and Src,
which suggests that both kinases contribute to breast can-
cer progression [33]. In a very recent study, levels of the
Figure 6 Cetuximab combined with lapatinib induces a cooperative antitumor effect in JIMT-1 tumor xenografts. (A) Seven days after
orthotopic injection of JIMT-1 cells, mice were randomized (10 per group) to receive cetuximab, lapatinib, or both (see Materials and methods for
details). The control group is constituted by animals treated with DMSO vehicle. The one-way ANOVA test was used to compare tumor sizes
among treatment groups at the median survival of the control group. Tumors were significantly smaller in mice treated with the combination
than in mice treated with a single agent (P < 0.1 × 10−2). (B) Mouse survival was evaluated up to day 49. (C) Western blot analysis of total lysates
from JIMT-1 tumor specimens of six mice killed on day 25. Tumors derived from each treatment group were pooled during lysis to obtain a single
specimen. The relative optical density of phospho-protein levels normalized to the actin level is shown.
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SKBR-3 cells with acquired resistance to lapatinib than in
parental cells, and this was coupled with persistent levels
of extracellular signal-regulated kinases 1/2 (ERK1/2) and
AKT activation [42]. Moreover, some activating mutations
in the catalytic subunit of PI3K could confer resistance to
lapatinib, thus requiring a dual PI3K/HER2 blockade [43].
Taken together, these data indicate that multiple alterations
could arise in lapatinib-resistant cells, and that robust in-
hibition of cancer cell proliferation could be achieved by
simultaneously blocking signaling pathways mediated by
different RTKs.
Here we demonstrated that, in cellular models of lapa-
tinib resistance, inhibition of HER2 or EGFR induced by
single-agent therapy did not exert any relevant biologic
effect, whereas the combination of lapatinib and cetuxi-
mab inhibited proliferation, migration, and invasion that,
in turn, seem to depend on Src activation. Inhibition ofHER2 alone is ineffective due to the sustained Src-
mediated EGFR activation, which is reflected by high
levels of pAkt and pMAPK in resistant cells after lapatinib
treatment. Our data suggest that, in acquired or constitu-
tive resistance to lapatinib, EGFR could drive alternative
escape pathways. In this context, lapatinib acts mainly as
an HER2 inhibitor without affecting EGFR phosphoryl-
ation, which is sustained by Src overactivation.
The role of EGFR-dependent and HER2-dependent sig-
naling in lapatinib resistance is also demonstrated by the
finding that cetuximab alone is not able to circumvent re-
sistance because of the presence of a still-active HER2 re-
ceptor. Consistently, the addition of Src inhibition to
cetuximab does not revert the resistant behavior, whereas
simultaneous blockade of EGFR and HER2 does. The
combination of cetuximab with lapatinib is extremely ac-
tive, both in vitro and in vivo, in reducing signaling trans-
duction under the control of these two cooperating
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tion that depletion of EGFR by siRNA knockdown does
not affect sensitivity to lapatinib in HER2-overexpressing
cells [44] and explains the differential effect of cetuximab
treatment. The anti-EGFR mAb binds the extracellular
domain of the receptor by competing with ligand binding,
and by inducing receptor internalization and consequent
degradation [36], thus reducing EGFR activation more
efficiently than lapatinib.
Our data could have clinical implications because co-
expression of EGFR and HER2 has been observed in
10% to 36% of primary human breast carcinomas, and it
is generally associated with a poorer prognosis compared
with breast carcinomas expressing a single receptor [45].
In addition, survival is shorter in breast cancer patients
expressing phosphorylated HER2 or both HER2 and
EGFR [46].
Conclusion
This study demonstrates that inhibition of Src kinase activity
could serve to revert constitutive or acquired resistance to
lapatinib in breast cancer. The mechanism by which Src
overactivation might sustain the resistant phenotype could
be attributed to a preferential functional interaction of Src
with EGFR rather than with HER2. These data could, at
least in part, explain the disappointing results of clinical tri-
als with Src inhibitors as single-agent therapy [47], and pro-
vide the rationale for testing novel therapeutic combinations
that might benefit HER-2-resistant breast cancer patients.
Additional files
Additional file 1: Supplementary methods (Combination effect;
Immunoprecipitation and Western blot analysis; ELISA assay; RNA
Interference; Quantification of Alu sequences for experimental
metastasis assay).
Additional file 2: Figure S1. Effect of lapatinib treatment, alone or in
combination with saracatinib, on the growth of human breast cancer cell
lines. (A) Percentage survival of MDA-MB-361, SKBR-3, BT474, KPL-4, MDA-
MB-361-LR, and JIMT-1 breast cancer cell lines grown in complete medium
and treated with lapatinib measured by MTT assay. Data represent the
mean (± standard deviation, SD) of three independent experiments,
each performed in triplicate, and are presented relative to control (cells
treated with DMSO). Error bars indicate SDs. (B) Synergistic effect of
saracatinib and lapatinib on breast cancer cell lines. Data represent the
plot of the combination index (CI), a quantitative measure of the degree of
drug interaction for a given end point of the inhibitory effect. The CI values
of <1, 1, and >1 indicate synergy, additivity and antagonism, respectively.
Each point is the mean of three different replicate experiments, each
performed in triplicate.
Additional file 3: Table S1. P values for the combination of saracatinib
and lapatinib (combination versus lapatinib) in breast cancer cells, as
measured by MTT assay depicted in Figure 1A.
Additional file 4: Table S2. P values for the combination of saracatinib
and lapatinib (combination versus saracatinib) in breast cancer cells, as
measured by migration and invasion assays depicted in Figure 2C.
Additional file 5: Figure S2. Saracatinib combined with lapatinib
inhibits micrometastasis formation in mice lungs. (A) Standard curve plot
(left) and amplification plot (right) derived from five points 1:10 serialdilutions of 200 ng starting human DNA. Each reaction was carried out in
triplicate. (B) Amplification of mouse DNA with ALU3-specific primers.
Amplification plot shows no product amplification. (C) Standard-curve plot
(left) and amplification plot (right) of four analyzed samples: control, red
curves (mean CT, 28.38), lapatinib-treated DNA-derived lung samples, green
curves (mean CT, 29.63), saracatinib-treated DNA-derived samples, – light-
green curves (mean CT, 30.20) and lapatinib plus saracatinib-treated DNA-
derived samples, light blue curves (mean CT, 33.16). Lungs from each group
were pooled during lysis to obtain a single specimen. Each amplification
was carried out in duplicate.
Additional file 6: Figure S3. Breast cancer cell lines express similar levels
of EGF and TGF-α. Percentage of human EGF (A) and TGF-α (B) secretion in
conditioned media from breast cancer cell lines cultured for 24 hours in
complete medium, as measured with ELISA assays. Data represent the mean
(±SD) of three independent experiments performed in triplicate. Error bars
indicate SDs.
Additional file 7: Figure S4. Cetuximab combined with lapatinib
interferes with migration-related transducers in lapatinib-resistant breast
cancer cells. (A) Western blot analysis of total cell lysates from MDA-
MB-361, SKBR-3, MDA-MB-361-LR, and JIMT-1 human breast cancer cell
lines grown in complete medium and treated with lapatinib (1 μM),
cetuximab (0.35 μM) or both. (B) MTT assay of MDA-MB-361 cells untreated,
treated with lipofectamine alone, transfected with pcDNA-EGFR or pcDNA
EGFR Y845F, and treated with lapatinib at the IC50 dose (0.2 μM.) for 3
consecutive days; **P < 0.005; Western blot analysis of total lysates of
protein expression in MDA-MB-361 cells transfected with wild-type
EGFR or Y845F-EGFR.
Additional file 8: Figure S5. EGFR inhibition interferes with survival,
migration, and invasion in lapatinib-resistant breast cancer cells. (A) Percentage
of survival of MDA-MB-361, MDA-MB-361-LR, and JIMT-1 breast cancer
cell lines grown in complete medium and treated with a constant dose
ratio (MDA-MB-361) or equipotent doses (MDA-MB-361-LR and JIMT-1)
of lapatinib and cetuximab, as measured with MTT assay. (B) Synergistic
effect of lapatinib and cetuximab on breast cancer cell lines. Data represent
the plot of combination index (CI). Each point is the mean of three different
replicate experiments, each performed in triplicate. (C) Percentage of
migration of MDA-MB-361, MDA-MB-361-LR, and JIMT-1 human breast
cancer cell lines grown in complete medium and treated with lapatinib
(1 μM), cetuximab (0.35 μM), and the combination, as measured by
wound-healing assay. (D) Percentage of invasion of MDA-MB-361,
MDA-MB-361-LR, and JIMT-1 human breast cancer cell lines grown in
complete medium and treated with lapatinib (1 μM), cetuximab
(0.35 μM), and the combination, as measured with fibroblasts monolayer
invasion assay. Data represent the mean (±standard deviation, SD) of
three independent experiments, each performed in triplicate, and are
reported relative to control (cells treated with DMSO). Error bars indicate
SDs. Asterisks indicate statistical significance of combined treatment versus
lapatinib alone, as determined with the Student t test (*, two-sided
P < 0.5 × 10−1; **two-sided P < 0.5 × 10−2).
Additional file 9: Table S3. P values for the combination of cetuximab
and lapatinib (combination versus lapatinib) in breast cancer cells, as
measured with MTT assay depicted in Additional file 5: Figure S5A.
Additional file 10: Figure S6. The saracatinib and cetuximab
combination does not inhibit survival of human breast cancer
lapatinib-resistant cell lines. (A) Percentage of survival of MDA-MB-
361-LR and JIMT-1 breast cancer cell lines grown in complete medium
and treated with equipotent doses (MDA-MB-361-LR and JIMT-1) of
saracatinib and cetuximab, as measured with MTT assay. Error bars
indicate SDs.
Additional file 11: Table S4. P values for the combination of
cetuximab and lapatinib (combination versus saracatinib) in breast cancer
cells, as measured with migration and invasion assays depicted in
Additional file 5: Figures S5C and S5D.Abbreviations
ATP: Adenosine triphosphate; DMSO: dimethyl sulfoxide; EGFR: epidermal
growth factor receptor; FAK: focal adhesion kinase; LR: lapatinib-resistant;
RTK: tyrosine kinase receptor; siRNA: small interfering RNA; TK: tyrosine kinase.
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